Se Cereno Scientifics presentation below.
At the BioStock Investor Meeting in Stockholm, Cereno Scientific's CEO Sten R. Sörensen spoke about the progress of the company's ongoing Phase II study with the lead candidate CS1 and the company's preclinical program. Cereno is also currently offering warrants of series T02, the subscription period of which runs between September 14 and 28. Cereno Scientific's Chief Medical Officer Björn Dahlöf also participated in the question and answer session.